Seres Therapeutics Inc
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
Case Summary | |
Company Name: | Seres Therapeutics Inc |
Stock Symbol : | NASDAQ: MCRB |
Class Period Start: | 06/25/2015 |
Class Period End: | 07/29/2016 |
Lead Plaintiff motion: | 11/28/2016 |
Date Filed: | 09/28/2016 |
Type of Case: | Securities Class Action |
Court: | U.S. District Court for the District of Massachusetts |
Summary: | Thieler Law Corp advises investors with losses exceeding $100,000 of the November 28, 2016 lead plaintiff deadline in a class action lawsuit filed against Seres Therapeutics Inc (NASDAQ:MCRB) ("Seres" or “the Company”). The suit is pending in the U.S. District Court for the District of Massachusetts and investors, who purchased Seres Therapeutics Inc securities between June 25, 2015 and July 29, 2016, have until November 28, 2016 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class. If you purchased Seres Therapeutics Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing mail@thielerlaw.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class. The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Seres Therapeutics advertised and hyped its lead drug product candidate SER-109 as “novel class of biological drugs” and a potential “first-in-field drug” despite knowledge that the Phase 2 clinical trial of SER-109 would fail to achieve its primary endpoint as compared to placebo. On July 29, 2016, The Company revealed in a press release that the Phase 2 clinical trial of SER-109, did not achieve its primary endpoint. President and Chief Executive Officer Roger Pomerantz also revealed that certain undisclosed modifications had been made to the formulation of SER-109 prior to the trial. Following this news, NASDAQ: MCRB dropped $26.04, or 72.8%, over the next two trading days, to close at $9.73 on August 1, 2016. If you were negatively impacted by your investment in Seres Therapeutics Inc securities between June 25, 2015 and July 29, 2016 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation. Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm. Thieler Law Corp 2534 State Street - Suite 406, San Diego, CA 92101 by email: mail@thielerlaw.com or telephone at +1 (619) 377 - 4324 or visit our website http://www.thielerlaw.com/ or Facsimile: +1 (619) 785 – 3185 |